Question 1

What makes tesamorelin different from other GH secretagogues?

Accepted Answer

Tesamorelin is the only GH secretagogue with current FDA approval, backed by Phase 3 clinical trial data in over 400 subjects. It is a full-length 44-amino acid GHRH analog with a chemical modification that extends its half-life, allowing effective GH stimulation from once-daily injection. Every other GH secretagogue (sermorelin, CJC-1295, ipamorelin, GHRP-2, MK-677) is either research-only or, in sermorelin's case, had FDA approval that was voluntarily discontinued. Tesamorelin's approval gives it a stronger regulatory and clinical evidence foundation than any alternative.

Question 2

Does tesamorelin actually reduce belly fat?

Accepted Answer

Yes, with a caveat: the fat reduction requires continued daily treatment to maintain. Phase 3 trials showed tesamorelin reduced visceral adipose tissue (the deep belly fat surrounding organs) by 15-18% over 26 weeks compared to a 1.2% gain in the placebo group (PMID: 20395564). When subjects switched from tesamorelin to placebo at week 26, VAT returned to pre-treatment levels within 12 weeks. This means tesamorelin suppresses visceral fat accumulation during active treatment rather than producing permanent fat loss. Results in the HIV lipodystrophy population may differ from results in otherwise healthy adults.

Question 3

Can tesamorelin improve cognitive function?

Accepted Answer

A 152-subject randomized controlled trial showed tesamorelin significantly improved executive function (P = 0.005) vs placebo over 20 weeks in adults aged 55-87, including both healthy older adults and those with mild cognitive impairment (PMID: 22869065). IGF-1 increased 117% and body fat decreased 7.4%. The cognitive benefits were comparable across healthy aging and MCI groups. The mechanism likely involves IGF-1-mediated neurogenesis and GH effects on cerebral metabolism. However, this was a single trial using a different population (older adults without HIV) than the approved indication.

Question 4

How does tesamorelin compare to HGH?

Accepted Answer

Tesamorelin stimulates the pituitary to produce GH naturally through the GHRH receptor, preserving the somatostatin feedback loop that prevents GH excess. Direct HGH (somatropin) bypasses these regulatory controls, producing flat, sustained GH levels that suppress the body's own production. Tesamorelin is not a controlled substance; HGH is Schedule III. For visceral fat reduction, Phase 3 data shows tesamorelin produces meaningful results comparable to HGH studies in the same population. HGH produces faster, more dramatic effects but carries higher risk of side effects, costs more, and has greater legal restrictions.

Question 5

How much does tesamorelin cost?

Accepted Answer

Commercial pharmacy pricing for Egrifta (brand tesamorelin) runs approximately $1,000-1,500 per month. Insurance coverage is sometimes available for the approved HIV lipodystrophy indication with appropriate documentation from an HIV specialist. For off-label use through anti-aging telehealth providers, compounded tesamorelin is available at approximately $200-400 per month. As with all compounded peptides, quality and purity can vary by pharmacy. The significant price difference between brand and compounded versions has driven most off-label use toward compounding pharmacy channels.

Tesamorelin: Frequently Asked Questions

What makes tesamorelin different from other GH secretagogues?

Does tesamorelin actually reduce belly fat?

Can tesamorelin improve cognitive function?

How does tesamorelin compare to HGH?

How much does tesamorelin cost?

Sources

Free Peptide Weight Loss Guide